On November 17, 2025 Nerviano Medical Sciences (NMS), a clinical-stage biopharmaceutical company focused on oncology innovation, reported that its subsidiary, Nerviano Medical Sciences (Shanghai) Co., Ltd. (NMS China), has officially joined the Roche Accelerator.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
NMS China is part of the Roche Accelerator since October 2025. The Roche Accelerator is Roche’s first in-house accelerator globally, representing Roche’s long-term commitment to Shanghai and China. The Roche Accelerator aims to catalyze and empower scientists and entrepreneurs to accelerate breakthrough innovation into next-generation therapeutics.
Joining the Roche Accelerator marks a new milestone for NMS China, reinforcing the company’s mission to bring differentiated cancer therapies to patients through scientific excellence and global partnerships.
Entrectinib, a precision oncology therapy approved for the treatment of NTRK and ROS1 fusion-positive cancers, originated from NMS and was out-licensed to Ignyta, subsequently acquired by Roche. This success story exemplifies NMS’s commitment to advancing transformative therapies from discovery to global reach.
"We are delighted to see Nerviano Medical Sciences join the Roche Accelerator," said Hugues Dolgos, Pharm.D, CEO of NMS Group and NMS Srl. "By bringing together Roche’s global innovation ecosystem and NMS’s deep oncology expertise, we aim to accelerate the translation of breakthrough science into impactful therapies for patients in China and around the world."
"Becoming part of Roche Accelerator is a significant step for NMS China," said Li Dadong, Ph.D., CEO of NMS China. "This partnership provides us with an invaluable environment to collaborate, innovate, and accelerate the development of our precision oncology programs."
NMS will continue to expand its research and development in oncology, focusing on targeted therapies, antibody–drug conjugates (ADCs), and mechanism-driven approaches to cancer treatment.
(Press release, Nerviano Medical Sciences, NOV 17, 2025, View Source [SID1234660023])